Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma
Ye‐Lin Liang(Sun Yat-sen University), Jing‐Ping Yun(Sun Yat-sen University), Xiaozhong Chen(Tokyo Institute of Technology), Yusheng Jie(Sun Yat-sen University), Min Hou(Affiliated Hospital of North Sichuan Medical College), Shubin Hong(Sun Yat-sen University), Guoxian Long(Tongji Hospital), Ying-Qing Li(Sun Yat-sen University), Yangying Zhou(Central South University), Yawei Yuan(Ruijin Hospital), Cheng‐long Huang(Sun Yat-sen University), Guangyuan Hu(Tongji Hospital), Huixia Feng(Sun Yat-sen University Cancer Center), Rui Sun(Sun Yat-sen University), Jie Lin(Guangzhou Medical University), Jing Huang(Sun Yat-sen University), Lusi Chen(Sun Yat-sen University), Kunyu Yang(Macau University of Science and Technology), Xu Liu(Sun Yat-sen University), Lei Chen(Zhuzhou Central Hospital), Hao Li(Uppsala University Hospital), Ning Zhang(Fudan University Shanghai Cancer Center), Fei Han(Shenyang Pharmaceutical University), Lin Li(Ningbo University), Ling Li(Tumor Hospital of Guangxi Medical University), Yaqin Wang(Sun Yat-sen University), Chunhua Chen(University of Science and Technology of China), Xiao‐Dong Zhu(Fudan University Shanghai Cancer Center), Liangfang Shen(Central South University), Cheng Xu(Sun Yat-sen University), Chuanben Chen(Fujian Medical University), Jie Tang(Panyu District Central Hospital), Li-Xia Lu(Sun Yat-sen University), Feng Jin(Guiyang Medical University), Guorong Zou(Panyu District Central Hospital), Ying Huang(Wuhan University), Ting Jin(Central Hospital of Wuhan), Yan-Ping Mao(Sun Yat-sen University), Ling-Long Tang(Sun Yat-sen University), Jingfeng Zong(Fujian Medical University), Sai-Wei Huang(Sun Yat-sen University), Xiuyun Gong(Guiyang Medical University), Wei-Han Hu(Sun Yat-sen University), Wen-Fei Li(Sun Yat-sen University), Fang-Yun Xie(Sun Yat-sen University), Guan-Qun Zhou(Sun Yat-sen University), Yu-Xiang He(Central South University), Yu‐Pei Chen(Sun Yat-sen University)
Cited by 67
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934
Analysis of the chemical diffusion coefficient of lithium ions in Li3V2(PO4)3 cathode material
|Electrochimica Acta|2009|643